We are live on ! Find out more
CP

Catalys Pacific Portfolio holdings

AUM $229M
1-Year Est. Return 100.3%
This Fund
S&P 500
This Quarter Est. Return
-9.5%
1 Year Est. Return
+100.3%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$132M
AUM Growth
-$15.6M
Cap. Flow
-$1.37M
Cap. Flow %
-1.04%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$1.37M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MLYS icon
1
Mineralys Therapeutics
MLYS
$2.37B
$108M 81.19%
9,194,579
HLVX
2
DELISTED
HilleVax
HLVX
$17.5M 13.19%
1,208,974
-100,000
-8% -$1.37M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$666M
$7.44M 5.61%
721,962

Similar funds

Catalys Pacific's Q2 2024 Portfolio in Review

As of Q2 2024, Catalys Pacific held 3 positions worth $132M, down 11% from $148M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2024: portfolio turnover was 0%. Catalys Pacific opened no new positions and made no exits, leaving the 3-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Catalys Pacific's biggest Q2 2024 reduction was HilleVax, cutting an estimated $1.37M.
  • Catalys Pacific's ten largest holdings make up 100% of its $132M portfolio in Q2 2024.
  • Catalys Pacific opened 0 new positions and closed 0 in Q2 2024.
  • Catalys Pacific's portfolio value fell 11% quarter-over-quarter to $132M.

Based on Catalys Pacific's 13F filing for Q2 2024, filed 13 Aug 2024.